ABOUT KALOCYTE
KaloCyte, Inc., a pre-clinical stage healthcare biotech startup company, is located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark and was selected as a BLUE KNIGHT™ company. KaloCyte’s offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was incorporated in 2016 by co-founders Dr. Doctor, Dipanjan Pan, PhD and Phil Spinella, MD – expert researchers in physiology, bioengineering, and trauma care. KaloCyte has demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $17M in NIH and DOD grants and over $5M in investor funding (cumulative to date).
KaloCyte History
- Featured in Science: The ultimate blood substitute? The U.S. military is betting $46 million on it / Science / AAAS
- Raised additional $0.7M of bridge round
- Team expanded to 10 employees, plus one intern
- Awarded DoD CMRP TTDA grant ($2.5M) for lyophilization optimization
- Subcontract for DARPA FSHARP expanded by $500K
- Maryland Tech Council ICON Awards finalist – Emerging Life Science CEO of the Year
- Qualified Maryland Biotech Company (QMBC) for State Biotech Investment Initiative Tax Credit (BIITC)
- Opened new bridge round, raised $1M
- Grew team to 9 employees, plus one intern
- Awarded NIH Phase 2B grant ($3M) for IND-enabling toxicology studies
- Subcontract for DARPA FSHARP $46M consortium award to UMB ($3.2M to KaloCyte)
- Comcast RISE Award recipient
- Maryland Tech Council ICON Awards finalist – Emerging Life Science Company of the Year
- Qualified Maryland Biotech Company (QMBC) for State Biotech Investment Initiative Tax Credit (BIITC)
- Finalist in the 8th Annual Biohealth Capital Region’s Crab Trap Pitch Event
- Raised $1M convertible note
- Expanded space, scientific team and expertise (total 8 employees); hosted first intern from UM School of Pharmacy (UM-SOP)
- Entered national phase with EM V2 patent filings in 11 target countries/regions
- Filed joint IP with UM for EM clearance system
- Awarded Maryland Industrial Partnerships (MIPS) Phase 2 grant ($100K) with UM-SOM
- Angel Capital Association Summit – Innovation Funders Showcase winner
- PitchForce A-Round – First Place winner
- Raised $1M convertible note
- Expanded scientific team with 2 new scientists (total 5 employees)
- Awarded NIH CRP SB1 grant ($500K)
- Filed and published EM V2 patent (US and PCT)
- Held Pre-IND Meeting with FDA CBER
- Awarded Maryland Industrial Partnerships (MIPS) Phase 1 grant ($100K) with UM-SOM
- Raised $1M convertible note
- Filed provisional patent application for lead candidate, EM V2
- Moved to Baltimore, MD as a University of Maryland (UM) BioPark Affiliate
- Leased lab and office space in new Center for Blood Oxygen Transport & Hemostasis (CBOTH) at UM School of Medicine (UM-SOM)
- Awarded NIH Ph1 SBIR grant ($375K)
- Subaward on Haima Therapeutics’ DoD CDMRP CRRP grant ($1.6M)
- Participated in NIH CAP accelerator program
- Held INTERACT Meeting with FDA
- First seed funding ($800K) equity
- Board of Directors expanded
- First scientists hired
- CEO recruited
- Startup Connection Event: Rubin Brown Award
- American Society Hematology (ASH), awarded “Best of ASH” & press release
- Awarded NIH NHLBI Fast Track STTR grant ($2M)
- Awarded DoD CDMRP grant ($3M)
- KaloCyte, Inc. formed as a Delaware C-Corporation
- Patents issued, ‘Quick Start License’ with WUSTL
- Board of Directors and Scientific Advisory Board form
by Drs. Pan, Doctor & Spinella
at Washington University in St. Louis (WUSTL)
- Bench Pilot Work
Formulation demonstrates key requirements
Novel transfusion models - First in vivo POC
Efficacy for hemorrhagic shock and 70% blood exchange
Formulation ErythroMer (EM) V1 - First Funding & Support
Children’s Discovery Institute OAIF Grant ($1M)
Invention Disclosure (WUSTL)
Bear Cub award ($75K) - Incubator Program: BioGenerator Fundamentals
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.